A Single-center, Open-label Trial, Investigating the Pharmacokinetics, Pharmacodynamics and the Safety Profile After a Single Oral Dose of Gemigliptin (Investigational Product) in Healthy Subjects and Subjects With Mild or Moderate Hepatic Impairment and After Multiple Oral Dose in Healthy Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Gemigliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 11 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Dec 2013 New trial record